新发传染病电子杂志2023，Vol.8Issue(6)：37-41,5.DOI:10.19871/j.cnki.xfcrbzz.2023.06.007
多替拉韦钠+拉米夫定两药方案在初治HIV感染/AIDS患者的临床观察
Efficacy observation of the two-drug regimen DTG+3TC in treatment-naive human immunodeficiency virus infection/acquired Immure deficiency syndrome patients
摘要
Abstract
Objective To investigate the clinical efficacy of a simplified regimen of dolutegr-avir(DTG)+lamivudine(3TC)in first-treatment human immunodeficiency virus infection/acquired immure deficiency syndrome patients.Method Historical control subgroups were selected,and primary HIV/AIDS patients who received antiretroviral therapy(ART)at the Chest Hospital of Guangxi Zhuang Autonomous Region between January 2019 and September 2022 were selected.According to the enrolment criteria,47 cases in the observation group were treated with DTG+3TC regimen,and 49 cases in the control group were treated with tenofovir(TDF)+ lamivudine(3TC)+ efavirenz(EFV)regimen,and the HIV suppression rate and immunological status of the two groups were compared with each other after 36 weeks of treatment under observation.Result In the baseline characteristics of the two groups,the difference in age distribution and baseline HIV RNA load capacity were statistically significant,with no significant difference in residual baseline index;at 12 week of treatment,the observation group and control group were 56.6%and 30.6%,respectively(P=0.011);at 24 weeks of treatment,the viral suppression rates of the two groups were 63.6%and 79.6%,respectively(P=0.139);at 36 weeks treatment,the viral suppression rates of the two groups were 85.1%and 81.6%,respectively(P=0.786),and the median CD4+T lymphocyte counts and CD4+/CD8+T lymphocyte ratios were significantly higher than those at baseline,and there was no significant difference in the magnitude of the increase between the two groups(P＞0.05).Conclusion The viral suppression effect of the simplified two-drug regimen of DTG+3TC in the treatment of first-treatment HIV/AIDS patients was not different from that of the triple-drug regimen of TDF+3TC+EFV,and even the early viral suppression rate was better than that of the triple-drug regimen of TDF+3TC+EFV,and at the same time it could effectively improve immune function.关键词
艾滋病/拉米夫定/多替拉韦钠/两药方案/临床疗效Key words
Acquired immure deficiency syndrome/Dolutegravir/Lamivudine/Two-drug regimen/Clinical efficacy分类
医药卫生引用本文复制引用
兰双来,蓝珂,张勇,窦艳云..多替拉韦钠+拉米夫定两药方案在初治HIV感染/AIDS患者的临床观察[J].新发传染病电子杂志,2023,8(6):37-41,5.基金项目
1.广西医疗卫生适宜技术开发与推广应用项目(S2020064) （S2020064）
2.柳州市科技计划项目(2020NBAD0801) （2020NBAD0801）
